MUMBAI: Pharma major Lupin Ltd is looking at strengthening branded portfolio with the launch of additional products developed and filed with the USFDA from its pipeline as well as through strategic brand acquisitions.
The company's US revenues grew by 54 per cent to Rs 3,683 crore during FY 2013, up from Rs 2,393 crore in FY 2012.
The brands business contributed 21 per cent of total US sales whereas the generics business contributed 79 per cent during FY 2013.
"The company aims to strengthen its branded portfolio with the launch of additional products developed and filed with the USFDA from its own pipeline as well as through strategic brand acquisitions," Lupin Managing Director Kamal K Sharma said in the annual report.
"The creation of an advanced bio-technology programme and expansion of a truly global novel drug discovery and development pipeline have added (another) dimension to the company's readiness to reinforce sustainability in the long-term", he added.
Lupin Pharmaceuticals, Inc (LPI), the company's US subsidiary headquartered in Baltimore, Maryland, remains the 5th largest generic player (by prescriptions) in the US and also the fastest growing generic pharma player in the top 5 for the fourth year running, growing at 6.3 percent, the report said.
Over the last few years, LPI has built one of the best generic products pipeline for the US market addressing a market opportunity valued at over USD 80 billion, according to the report.
The US generics business in FY'13 can be best summarised as a year of milestones, it said, adding that the company surpassed USD 500 million in revenues from its generics business for first time, clocking in growth of 70 per cent.
New launches contributed 42 per cent of the US generics revenues, the company said.